Sept. 25, 2007--At the 2007 UBS Global Life Sciences Conference, Incyte Corporation (Nasdaq:INCY) will announce positive proof-of-concept clinical results from the following trials:... an ongoing 28-day Phase IIa placebo-controlled two-step hyperinsulinemic clamp trial in Type 2 diabetes for INCB13739, its lead orally available 11beta-HSD1 inhibitor... Incyte's Press Release - UBS Global Life Sciences Conference [PDF Agenda] -
